The Role of Beta-Hydroxybutyrate in Mitigating the Inflammatory and Metabolic Consequences of Uric Acid
Metabolites · 04.12.2024 · 14 (12) · 679
DOI: 10.3390/metabo14120679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolites, online erschienen am 04.12.2024. Verfasst von Nicole P Remund und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anderson Active Ingredients.
Abstract (Originalsprache)
Background
Uric acid (UA), a metabolite of purine and fructose metabolism, is linked to inflammation and metabolic disorders, including gout and cardiovascular disease. Its pro-inflammatory effects are largely driven by the activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, leading to increased cytokine production. Beta-hydroxybutyrate (BHB), a ketone produced during fasting or carbohydrate restriction, has been shown to reduce inflammation. This study explores the role of BHB in mitigating the inflammatory and metabolic effects of elevated uric acid levels.
Methods
We utilized a murine muscle cell culture treated with UA and BHB.
Results
Muscle cells treated with UA had increased production of pro-inflammatory cytokines and reduced cell viability. Co-treatment with BHB reversed these effects, improving cell survival and reducing cytokine levels. Additionally, uric acid impaired mitochondrial function and increased oxidative stress, which were mitigated by BHB. Furthermore, uric acid disrupted insulin signaling, but BHB co-treatment restored insulin sensitivity.
Conclusions
These findings suggest that BHB holds therapeutic potential by counteracting the inflammatory and metabolic disruptions caused by elevated uric acid, making it a promising target for conditions such as hyperuricemia and metabolic syndrome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
- Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
ORCID-Profile: Paul R Reynolds
Förderung
- Anderson Active Ingredients
Zitieren
APA
Remund, N. P., Larsen, J. G., Shin, M. J., Warren, C. E., Palmer, I. L., Kim, I. J., Cooper-Leavitt, E. T., Clarke, D. M., Beus, C. G., Johnson, R. J., Arroyo, J. A., Reynolds, P. R., & Bikman, B. T. (2024). The Role of Beta-Hydroxybutyrate in Mitigating the Inflammatory and Metabolic Consequences of Uric Acid. Metabolites, 14(12), 679. https://doi.org/10.3390/metabo14120679
Vancouver
Remund NP, Larsen JG, Shin MJ, Warren CE, Palmer IL, Kim IJ, et al. The Role of Beta-Hydroxybutyrate in Mitigating the Inflammatory and Metabolic Consequences of Uric Acid. Metabolites. 2024;14(12):679. doi:10.3390/metabo14120679
BibTeX
@article{Remund2024,
author = {Remund, Nicole P and Larsen, John G and Shin, Marley J and Warren, Cali E and Palmer, Isabelle L and Kim, Iris J and Cooper-Leavitt, Elijah T and Clarke, Derek M and Beus, Colson G and Johnson, Richard J and Arroyo, Juan A and Reynolds, Paul R and Bikman, Benjamin T},
title = {The Role of Beta-Hydroxybutyrate in Mitigating the Inflammatory and Metabolic Consequences of Uric Acid},
journal = {Metabolites},
year = {2024},
volume = {14},
number = {12},
pages = {679},
doi = {10.3390/metabo14120679}
}
EUVIMED